麻豆传媒

OTX-TKI may cut injection frequency by 90% while maintaining safety and efficacy

Capturing how efficacy is achieved in clinical practice could change treatment patterns

Using a viral vector to help the eye produce its own anti-VEGF proteins

One-time injection demonstrated 89% reduction of vision-threatening events

This could become the first line of therapy for DME, says Hani Salehi-Had, MD

Two phase III trials show durable improvement with fewer injections

Rahul Khurana, MD, discusses the risk factors

80% of patients were rescue-free up to 6 months with a single implant injection

Treatment does not reverse atrophy, but slows progression and preserves function